New Horizons in the Treatment of Corneal Endothelial Dysfunction
Carlos Rocha‐de‐Lossada, Rahul Rachwani‐Anil, Davide Borroni, José‐María Sánchez‐González, Raquel Marques, Fernando-Luis Soler-Ferrández, Jose-Antonio Gegúndez-Fernández, Vito Romano, Eitan Livny, Marina Rodríguez‐Calvo‐de‐Mora
Abstract
The treatment of corneal endothelial dysfunction has experienced a revolutionary change in the past decades with the emergence of endothelial keratoplasty techniques: descemet stripping automated endothelial keratoplasty (DSAEK) and descemet membrane endothelial keratoplasty (DMEK). Recently, new treatments such as cultivated endothelial cell therapy, Rho-kinase inhibitors (ROCK inhibitors), bioengineered grafts, and gene therapy have been described. These techniques represent new lines of treatment for endothelial dysfunction. Their advantages are to help address the shortage of quality endothelial tissue, decrease the complications associated with tissue rejection, and reduce the burden of postoperative care following transplantation. Although further randomized clinical trials are required to validate these findings and prove the long-term efficacy of the treatments, the positive outcomes in preliminary clinical studies are a stepping stone to a promising future. Our aim is to review the latest available alternatives and advancements to endothelial corneal transplant.